Research by Weizmann Institute scientist and Israel Prize winner saved 'countless lives,' was basis for technology sold for ...

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

A team of researchers led by NYU Tandon School of Engineering's Weiqiang Chen has developed a miniature device that could ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $69.0, a high ...

A Martin County family with a child fighting rare cancer is getting help from the community to get treatment abroad.

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...